Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis.
10.1007/s11596-015-1481-7
- Author:
Jun SHAO
1
;
Jie YANG
2
;
Jun-nai WANG
3
;
Long QIAO
3
;
Wei FAN
4
;
Qing-lei GAO
5
;
Yao-jun FENG
6
Author Information
1. Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China. tjjyang@126.com.
2. Cancer Biology Research Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. yangjie@tjh.tjmu.edu.cn.
3. Cancer Biology Research Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
4. Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China.
5. Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China. qlgao@tjh.tjmu.edu.cn.
6. Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China. 37865915@qq.com.
- Publication Type:Journal Article
- Keywords:
BRCA2 gene mutation;
familiar breast cancer;
overall survival rate
- MeSH:
BRCA2 Protein;
genetics;
Breast Neoplasms;
genetics;
mortality;
pathology;
Female;
Gene Expression;
Genetic Counseling;
Genetic Predisposition to Disease;
Humans;
Mutation;
Odds Ratio;
Prognosis;
Survival Analysis
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(5):629-634
- CountryChina
- Language:English
-
Abstract:
Reports of BRCA2 genetic mutations on the prognosis of familial breast cancer (BC) patients have been contradictory. True difference in survival, if it exists, would have important implications for genetic counseling and in treatment of hereditary BC. The purpose of this study was to compare overall survival rate (OSR) among BRCA2 mutation carriers, non-carriers and sporadic BC patients. We searched the PUBMED and EMBASE databases and retrieved 4529 articles using keywords that included breast cancer, BRCA, prognosis and survival. Nine articles were selected for systematic review and among them 6 were included in our meta-analysis. We used the fixed and random effect models to calculate the summary odds ratio (OR) and corresponding 95% confidence interval (CI). BRCA2 mutation carriers had significantly higher long-term OSR than non-carriers (OR=0.69 [95% CI=0.5-0.95]), while both short-term and long-term OSR of BRCA2 mutation carriers did not differ from those of patients with sporadic disease (OR=1.11 [95% CI=0.74-1.65]; 0.85 [95% CI=0.38-1.94], respectively). For BC-specific survival rate (BCSSR), BRCA2 mutation carriers had a similar BCSSR to the non-carriers (OR=0.61 [95% CI=0.28-1.34]). There was no significant difference in disease-free survival (DFS) between BRCA2 mutation carriers and patients with sporadic disease. Our results suggest that BRCA2 mutation increases long-term OSR in hereditary BC, which reminds us a new prospect of management of the disease.
